Researchers reported that microwave ablation can trigger more than direct tumor cell destruction, with a new preclinical study suggesting benefit from pairing the treatment with anti–LAG-3 immune checkpoint therapy. Published in Cancer Immunology, Immunotherapy, the work indicates the combination can strengthen CD8+ T cell antitumor activity. The study positions microwave ablation as a way to remodel the tumor microenvironment in favor of checkpoint blockade, aiming to overcome the limits of monotherapy in locally treated solid tumors. If the immune activation holds up, the approach could expand the role of locoregional procedures into systemic immune-oncology strategies. As a concept, the findings reinforce ongoing interest in combining physical tumor-local therapies with immunomodulators, but the results remain at the study stage described in the report. The next step would be to validate mechanistic immune signatures and durability in additional models and eventually in early clinical testing.